Company News

Participating in Bio Korea 2022, raising visitors’ expectations for ‘cell culture medium’ by introducing CELLiST 

‘CELLiST’, a brand of Ajinomoto Genexine, a cell culture medium specialist company, announced that it had successfully completed its participation in ‘Bio Korea 2022’ held at COEX in Seoul from the 11th to the 13th.

Bio Korea 2022 was held for three days with the participation of 624 bio industry companies, government agencies, and research institutes from 52 countries. Ajinomoto Genexine focused on introducing the strengths of CELLiST cell culture medium to visiting customers at the ‘Bio Korea 2022’ expo.

The booth introduces the cell culture medium product brand 'CELLiST', including high-performance chemical medium, and the 'Switch Program', a cell culture medium change system, so that visitors can take a look at the cell culture medium at a glance. An environment was created.

A CELLiST official said, “Through this Bio Korea 2022 expo, CELLiST’s sophisticated booth design with its unique characteristics captured the attention of many visitors and raised expectations,” adding, “Please look forward to the various systems and services that will be introduced in the future.”

Meanwhile, CELLiST is introducing a cell culture medium containing high-quality amino acids based on Ajinomoto Genexine's amino acid research capabilities and expertise, providing excellent cell growth speed and protein production ability at the same time.

In addition, Ajinomoto Genexine was established in Songdo, Incheon in 2012 to stably supply cell culture media, a key raw material for biopharmaceuticals, to the domestic market. As Korea's first cell culture medium manufacturing company, we supply cell culture medium for the manufacture of clinical reagents and commercially available biopharmaceuticals. In addition, in order to support customers using CELLiST, we plan to establish new bases in China and India, centered on Korea's CSC (CELLiST Solution Center), to provide products and services to customers not only in Korea but throughout Asia.

Through the media switch program that changes existing cell culture media to the CELLiST series, we are supporting our customers to improve productivity and antibody quality and reduce production costs.